MedTrace Logo

Use of Mucolytic Solution Before Upper Endoscopy

NCT04641455 · Status: UNKNOWN · Phase: NA · Type: INTERVENTIONAL · Enrollment: 120

Last updated 2020-11-23

No results posted yet for this study

Summary

The study was designed to evaluate the effectiveness of the maximum dose of mucolytic solution used before upper endoscopy on the visibility of the gastric mucosa

Conditions

Interventions

DRUG

Espumisan, N acetylcystein

Administration of mucolytic solution before upper endoscopy (Espumisan 320 mg, ACC long 600 mg)

DRUG

Espumisan, N acetylcystein

Administration of mucolytic solution before upper endoscopy (Espumisan 20 mg, ACC long 200 mg)

DRUG

Water

Administration of water before upper endoscopy

Sponsors & Collaborators

  • Vitkovice Hospital

    lead OTHER

Principal Investigators

  • Michal Stepan, M.D. · Digestive Diseases Center, Vítkovice Hospital

Study Design

Allocation
RANDOMIZED
Purpose
DIAGNOSTIC
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-12-01
Primary Completion
2021-05-30
Completion
2021-06-30

Countries

  • Czechia

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04641455 on ClinicalTrials.gov